policy

First Opinion By Laura E. Riley and Brenna L. Hughes

Pregnant and lactating women should not be excluded from Covid-19 drug, vaccine trials

Politics By Lev Facher and Nicholas Florko

Trump promises seniors $200 prescription drug gift certificates, but questions abound

D.C. Diagnosis By STAT staff

STAT+ Conversations: The D.C. Diagnosis

Politics By Lev Facher

Biden-aligned group outlines potential Day 1 drug pricing actions

First Opinion By Luciana Borio and Jesse L. Goodman

A vaccine alone won’t stop Covid-19. We also need a trusted plan for it

Politics By Nicholas Florko and Lev Facher

Trump’s last-ditch drug pricing moves could help him in November. But they likely won’t save Americans money

Politics By Nicholas Florko

With election looming, Trump releases major, last-ditch drug pricing order

Politics By Lev Facher

A Senate race in Kansas between two doctors sets the stage for an election hyper-focused on health policy — and on Covid-19

First Opinion By Josephine Johnston

The U.S. must do some heavy lifting to prepare for heritable genome editing

Politics By Nicholas Florko

How Trump could use a rare regulatory maneuver to lower drug prices before Election Day, and how it could backfire 

First Opinion By Stephen Patrick

The lack of a national policy agenda for children during Covid-19 — and beyond — causes grave harm

Politics By Nicholas Florko

New poll shows wide support for several Trump drug pricing reforms, but not rebate changes

Health By Lev Facher

Trump pledges a Covid-19 vaccine by end of 2020 — without acknowledging the scientific uncertainty

Politics By Nicholas Florko

Drug industry lobbyists circulate two drug pricing proposals in hopes of warding off a Trump executive order

Politics By Nicholas Florko and Lev Facher

As Covid-19 pressures mount, political newcomer Stephen Hahn struggles to protect an FDA under siege

Exclusive By Nicholas Florko and Lev Facher

PhRMA scrambles to respond to Trump’s drug pricing ultimatum, as Monday deadline looms

Politics By Lev Facher

‘No miracle is coming’: In acceptance speech, Biden rips Trump for Covid-19 mismanagement

Pharmalot By Ed Silverman

Drug makers seek to curtail discounts paid to hospitals as part of a controversial federal program

Politics By Juliet Isselbacher

‘A powerful shift’: Disability advocacy, once an afterthought in presidential races, gains new traction

STAT+ Conversations By Rick Berke, Erin Mershon, and Lev Facher

STAT+ Conversations: How pharma is influencing the 2020 election

Politics By Nicholas Florko

Trump orders government to buy certain drugs solely from U.S. factories, setting up major shakeup for industry

Politics By Amy Sokolow

Scientists are testing pricey rare-disease drugs as Covid-19 treatments. What if one works?

Politics By Nicholas Florko

The FDA is finalizing its long-awaited rules for CBD

Politics By Nicholas Florko and Lev Facher

The drug industry’s new tactic in Washington: calling Trump’s bluff 

Pharmalot By Ed Silverman

Seeking to battle high drug prices and the opioid crisis, two states ponder banning gifts to doctors

Politics By Nicholas Florko and Lev Facher

Trump administration unveils executive orders to curb drug prices — but they come with caveats

Health Tech By Natalya Ortolano

‘X to the Z’: San Francisco official pushes city to condemn public hospital’s Zuckerberg name

Politics By Nicholas Florko

The FDA got a lot more flexible during Covid — and pharma’s already pushing to make it permanent

Health Tech By Rebecca Robbins

Health tech companies are shelling out more to lobby Washington during the pandemic